Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis?

Disease-modifying therapies (DMTs) for multiple sclerosis (MS) have developed tremendously over the last 2 decades. Currently, more than 16 different products targeting various immunologic components have been approved for MS treatment in several countries.

Source: Neurology - September 11, 2017 Category: Neurology Authors: Wiendl, H., Bourdette, D., Ciccarelli, O. Tags: All Clinical trials, Multiple sclerosis EDITORIALS Source Type: research